Why Halberd Corporation Selected ASU And Where They Stand Among Other Universities

Jackson Center, PA, September 2, 2020 – Halberd Corporation (OTC PINK: “HALB“) today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment.

ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services funding among all U.S. institutions without a medical school, placing them ahead of Princeton, Georgia Tech and Carnegie Mellon University.  Moreover, U.S. News and World Report named ASU as the most innovative university each year from 2016 -2020, ranking it ahead of such notable institutions as Stanford and MIT.

William A. Hartman, Halberd’s Chairman, President & CEO stated, “Before engaging ASU, we reviewed six major universities in the United States. After evaluating all pertinent factors necessary for an institutional research partner, we determined that ASU met all of our criteria. ASU is a highly rated university in research and innovation, and we are fortunate to have them working with us on our project to develop a curative treatment for Covid-19. The efforts will also extend to treatments for other blood-borne and neurologic diseases using our patented extracorporeal treatment process. Halberd seeks a robust treatment beyond coronavirus yielding a pandemic-free society.”

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133

Twitter:@HalberdC

About Arizona State University.

Arizona State University is a public research university with 5 campuses in and around Phoenix, with four regional centers throughout Arizona.  It is one of the largest public universities, based on enrollment, and one of the fastest growing research universities in the United States. The school boasts over 400 National Academies-honored faculty, and 77 elite programs.

About Halberd Corporation.

Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” and “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus.”  Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.